CurrentCignaPolicy N/A

Parkinson's Disease - Inbrija Prior Authorization Policy

Prior authorization policy for coverage of Inbrija under Cigna-administered health benefit plans, specifying clinical criteria for FDA-approved indication (intermittent treatment of 'off' episodes in Parkinson's disease) and exclusion of other uses. Requires specialist prescribing or consultation and documents contraindications.

Policy Summary

PayerCigna

PolicyParkinson's Disease - Inbrija Prior Authorization Policy

Policy CodePolicy N/A

Change TypeRemoval of prior treatment trial requirementclarifying note placementadministrative updates

Effective Date

Next Review Date

Key ActionPrior Authorization is recommended for Inbrija; approvals are for 1 year when criteria are met and Inbrija must be prescribed by or in consultation with a neurologist.

SourceLink

POLICY UPDATE CHANGES

Requirement for a trial of one other treatment for 'off' episodes and documentation of significant intolerance or inadequate efficacy was removed.

Examples of evidence of 'off' episodes were moved to a Note.

Annual revision noted 'No criteria changes' on 09/20/2023.

1Covered Indication(s)

1 yearTypical Approval Duration

NeurologistSpecialist Prescriber Required

Coverage Summary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Scope: Prior authorization policy for coverage of Inbrija (levodopa inhalation powder) under Cigna-administered health benefit plans for the FDA-approved indication of intermittent treatment of 'off' episodes in patients with Parkinson's disease receiving carbidopa-levodopa. Coverage stance: covered_with_criteria. Typical approval duration: 1 year when criteria are met.

Key Facts

IndicationInbrija (levodopa inhalation powder) for Parkinson's disease 'off' episodes

Coverage Stancecovered_with_criteria

Typical Approval Duration1 year

Specialist RequiredNeurologist

Medical Necessity Criteria

FDA-Approved Indication — Parkinson's Disease

Approve for 1 year if the patient meets ALL of the following (A, B, C, and D):

FDA-Approved Indication — Parkinson's Disease: required criteria

A: Patient is currently taking carbidopa-levodopa
B: Patient is experiencing 'off' episodes
Examples of 'off' episodes include muscle stiffness, slow movements, or difficulty starting movements.
C: Patient does not have asthma, chronic obstructive pulmonary disease, or other chronic underlying lung disease
D: Inbrija is prescribed by or in consultation with a neurologist

Not Medically Necessary / Experimental Uses

Conditions not covered

Exclusion - experimental/unproven uses: Inbrija (levodopa inhalation powder - Acorda) is considered experimental, investigational or unproven for ANY other use(s)

Provider Actions & Authorization

Prior Authorization

Prior authorization required

Prior Authorization is recommended for prescription benefit coverage of Inbrija; approvals provided for duration of 1 year when criteria are met.

Documentation Required

Specialist prescribing/consultation requirement

Inbrija must be prescribed by or in consultation with a neurologist (physician who specializes in the condition being treated).

Denial Risk

Contraindication / exclusion risk

Claims may be denied or not approved if the patient has asthma, chronic obstructive pulmonary disease, or other chronic underlying lung disease, or if Inbrija is used for indications other than intermittent 'off' episodes in Parkinson's disease.

Background & Evidence

Background: Inbrija is indicated for the intermittent treatment of 'off' episodes in patients with Parkinson's disease treated with carbidopa-levodopa. Evidence reviews note that the rapid-onset levodopa drug class has insufficient evidence and is considered investigational for treatment of motor fluctuations in some reviews.

Source	Reference
Prescribing information	Inbrija inhalation powder [prescribing information], Acorda; December 2022
Guideline review	International Parkinson and Movement Disorder Society evidence-based review (Mov Disord. 2018;33(8):1248-1266) indicates insufficient evidence for rapid-onset levodopa drug class for motor fluctuations.

Definitions

'Off' episodesPeriods when Parkinson's disease symptoms return; examples include muscle stiffness, slow movements, or difficulty starting movements.

Revision History

03/20/2024material

Requirement for a trial of one other treatment for 'off' episodes and documentation of significant intolerance or inadequate efficacy was removed.

03/12/2025non-materialLatest

Examples of evidence of 'off' episodes were moved into a Note (examples include muscle stiffness, slow movements, or difficulty starting movements).

09/20/2023non-material

Administrative annual review noted 'No criteria changes'.